How to combine hormonotherapy and radiation treatment in adjuvant breast cancer?;Cancers du sein : comment associer l'hormonothérapie et la radiothérapie en situation adjuvante ?

Cancer/Radiotherapie

Volumn 12, Issue 1, 2008, Pages 37-41

  Azria, D ^a   Ozsahin, M ^b   Gligorov, J ^c   Zaman, K ^b   Llacer Moscardo, C ^a   Lemanski, C ^a   Jacot, W ^a   Belkacemi Y ^d  

^a CENTRE VAL D AURELLE   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HÔPITAL TENON   (France)

^d UNIV LILLE   (France)

Author keywords

Adjuvant; Breast cancer; Concomitant; Hormonotherapy; Radiotherapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; HORMONE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; IRRADIATION; LYMPHOCYTE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHORT SURVEY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; RADIOTHERAPY, ADJUVANT; TAMOXIFEN;

EID: 40149096963     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.11.010     Document Type: Short Survey

References (32)

1. Azria D., Gourgou S., Jeanneret-Sozzi W., Zouhair A., Mirimanoff R.O., Kramar A., et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 91 (2004) 1251-1260
2. Azria D., Lemanski C., Zouhair A., Gutowski M., Belkacemi Y., Dubois J.B., et al. Hormonoradiothérapie adjuvante concomitante des cancers du sein̊: état de l'art. Cancer Radiother 8 (2004) 188-196
3. Azria D., Larbouret C., Cunat S., Ozsahin M., Gourgou S., Martineau P., et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 7 (2005) R156-R163
4. Azria D., Pelegrin A., Dubois J.B., Mirimanoff R.O., and Ozsahin M. Radiation therapy and tamoxifen: concurrent or sequential? It's no longer the question!. J Clin Oncol 23 (2005) 4239-4241
5. Belkacémi Y, Laharie-Mineur H, Gligorov J, Azria D. Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer. Cancer Radiother 2007;11:266-75.
6. Bentzen S.M., Skoczylas J.Z., Overgaard M., and Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 88 (1996) 918-922
7. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
8. Butta A., MacLennan K., Flanders K.C., Sacks N.P., Smith I., McKinna A., et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52 (1992) 4261-4264
9. Canney P.A., and Dean S. Transforming growth factor beta: a promotor of late connective tissue injury following radiotherapy?. Br J Radiol 63 (1990) 620-623
10. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1-98. J Clin Oncol 25 (2007) 486-492
11. Colletta A.A., Wakefield L.M., Howell F.V., van Roozendaal K.E., Danielpour D., Ebbs S.R., et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 62 (1990) 405-409
12. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 350 (2004) 1081-1092
13. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
14. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
15. Fowble B., Fein D.A., Hanlon A.L., Eisenberg B.L., Hoffman J.P., Sigurdson E.R., et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 35 (1996) 669-677
16. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
17. Kantorowitz D.A., Thompson H.J., and Furmanski P. Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma. Int J Radiat Oncol Biol Phys 26 (1993) 89-94
18. Koc M., Polat P., and Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol 64 (2002) 171-175
19. Martin M., Lefaix J.L., Pinton P., Crechet F., and Daburon F. Temporal modulation of TGF-beta 1 and beta-actin gene expression in pig skin and muscular fibrosis after ionizing radiation. Radiat Res 134 (1993) 63-70
20. Mauriac L., Keshaviah A., Debled M., Mouridsen H., Forbes J.F., Thurlimann B., et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18 (2007) 859-867
21. Osborne C.K., Boldt D.H., Clark G.M., and Trent J.M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43 (1983) 3583-3585
22. Ozsahin M., Crompton N.E.A., Gourgou S., Kramar A., Li L., Shi Y., et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 11 (2005) 7426-7433
23. Paulsen G.H., Strickert T., Marthinsen A.B., and Lundgren S. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol 35 (1996) 1011-1019
24. Sarkaria J.N., Fowler J.F., Lindstrom M.J., Jordan V.C., and Mulcahy R.T. The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot). Int J Radiat Oncol Biol Phys 31 (1995) 833-840
25. Sarkaria J.N., Miller E.M., Parker C.J., Jordan V.C., and Mulcahy R.T. 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res Treat 30 (1994) 159-165
26. Schmidt-Ullrich R.K., Valerie K., Chan W., Wazer D.E., and Lin P.S. Expression of oestrogen receptor and transforming growth factor-alpha in MCF-7 cells after exposure to fractionated irradiation. Int J Radiat Biol 61 (1992) 405-415
27. Sinclair W.K. Cyclic x-ray responses in mammalian cells in vitro. Radiat Res 33 (1968) 620-643
28. Taylor M.E., Perez C.A., Halverson K.J., Kuske R.R., Philpott G.W., Garcia D.M., et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 31 (1995) 753-764
29. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
30. Toledano A., Garaud P., Serin D., Fourquet A., Bosset J.F., Miny-Buffet J., et al. La chimothérapie concomitante augmente la toxicité tardive après chirurgie conservatrice du cancer du sein. Cancer Radiother 10 (2006) 158-167
31. Wazer D.E., DiPetrillo T., Schmidt-Ullrich R., Weld L., Smith T.J., Marchant D.J., et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 10 (1992) 356-363
32. Wazer D.E., Tercilla O.F., Lin P.S., and Schmidt-Ullrich R. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17β-estradiol and tamoxifen. Br J Radiol 62 (1989) 1079-1083